Navigation Links
Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
Date:1/8/2014

MOUNTAIN VIEW, Calif., Jan. 8, 2014 /PRNewswire/ -- The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Although highly efficacious, existing VEGF treatments require frequent, invasive intravitreal injections. Thus, growth opportunities exist for new therapies with comparable efficacy but improved dosing and administration.

New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) Analysis of the US Retinal Therapeutics Market finds the market earned revenue of $2.45 billion in 2012 and estimates this to almost double to $4.15 billion in 2017.

For more information on this research, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"Despite the popularity of VEGF inhibitors in the U.S., issues of patient preference and compliance, the risk of infection, as well as side effects such as floaters, increased intraocular pressure and inflammation of the eye exist," said Frost & Sullivan Life Sciences Senior Industry Analyst Debbie Toscano. "There is also a lack of substantive long term data on the ability of VEGF therapy to prevent visual impairment."

In addition, the rapid uptake of low-cost Avastin, supplied by compounding pharmacies, is challenging the VEGF inhibitors market. Although the U.S. Food and Drug Administration has drawn attention to safe
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Cleared for Quotation on OTCQB
2. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
3. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
4. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
5. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
6. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
7. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
8. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
9. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
10. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
11. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 28 MedQuist Inc. (Nasdaq: MEDQ ... and a leader in technology-enabled clinical documentation workflow, ... (CAC) technology for improved coding productivity, efficiency, cost ... Spring, MedQuist vice president of Product Management, "CodeRunner ...
... Holdings, Inc. (OTC Bulletin Board: ADLS ... commercialization of novel drugs in the therapeutic areas of infection, ... million of proceeds from the exercise of the unit warrants ... 1, 2010. Each unit warrant entitled its holder to purchase ...
Cached Medicine Technology:MedQuist Introduces CodeRunner™ With Computer-Assisted Coding 2Advanced Life Sciences Receives $1.5 Million From Exercise of Unit Warrants and Secures Financing Commitment 2Advanced Life Sciences Receives $1.5 Million From Exercise of Unit Warrants and Secures Financing Commitment 3
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
(Date:1/22/2015)... is a famous dress online store for wedding dresses and ... collection of wedding dresses , and launches a site-wide women’s ... dress on your big day; the wedding gown is the ... to find the most suitable wedding dress. Now, we are ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... (NYSE Amex: FHC ) today announced that it ... Approval of the FC2 Female Condom(R) on Thursday, ... The Company announced its receipt of FDA approval for the ... today. Shareholders and other interested parties may participate in the ...
... a featured part of one of the fastest-growing ... HCPLive.com today announced a traffic- and revenue-sharing ... the most widely read physician blogs. KevinMD.com, home ... medical news, is written by Kevin Pho, MD, ...
... NEW YORK, March 11 JLL Patheon Holdings, LLC, an ... will be commencing its previously announced offer for any and ... Patheon Inc. ("Patheon") that it does not already own at ... Restricted Voting Share, which is equivalent to approximately C $2.57 ...
... Washington becomes 2nd state to legalize procedure , , ... suffering is the leading reason why terminally ill patients ... Act, according to an Oregon Health & Science University ... requested physician aid in dying or had contacted an ...
... Birner Dental Management Services, Inc. (Nasdaq: BDMS ... practices announced its regular quarterly dividend. The Company,s board ... cents per share of common stock. The dividend is ... 2009.Birner Dental Management Services, Inc. acquires, develops, and manages geographically ...
... pragmatic message of the "Food for Thought" podcast by ... 11 "If we don,t have time to be ... healthy" is how Colleen Patrick-Goudreau begins her 100th episode ... her signature combination of humor and wisdom to inspire ...
Cached Medicine News:Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 3Health News:KevinMD.com Joins the HCPLive.com Network 2Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 2Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 3Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 4Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 5Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 6Health News:Fear of Pain Drives Requests for Assisted Death 2Health News:'Life-Changing' Podcast Celebrates Its 100th Episode with Food for Thought on Eating Healthfully in a Recession 2
... information technology platform, the VERICIS Cardiovascular ... different sites (office, clinic, hospital) and ... angiography, echo, nuclear, MR, hemodynamics, reports, ... record on the cardiac patient. ...
... The compact UW7 Bidirectional Doppler has the operating ... LED's on the probe tip indicate the direction ... is also controlled on the probe tip. These ... control. ,The pencil style probe and cable are ...
... The first of an exciting new ... (Optical Low Coherence Reflectometry) technology,our Slitlamp-mounted* ... of 1m and this non-contact.,This ... at any time,and without concerns about ...
... graphic display and IOL power calculation software. ... include firmware module with SRKII, SRKT, Holladay ... tones increase in frequency the closer you ... alignment is achieved with corneal indentation. Triple ...
Medicine Products: